Efficacy and safety of therapy with biosimilar bevacizumab in the treatment of patients with metastatic colon cancer -a series of clinical observations
- Authors: Fedyanin M.Y.1, Elsnukaeva K.K.1, Pokataev I.A1, Sekhina O.V1, Chekini D.A1, Bulanov A.A1, Tryakin A.A1, Tyulyandin S.A1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: No 12 (2018)
- Pages: 55-59
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295811
- DOI: https://doi.org/10.18565/pharmateca.2018.12.55-59
- ID: 295811
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Mikhail Yu. Fedyanin
N.N. Blokhin National Medical Research Center of Oncology
Email: fedianinmu@mail.ru
MD, Senior Researcher at the Department of Clinical Pharmacology and Chemotherapy
Kh. Kh.-M Elsnukaeva
N.N. Blokhin National Medical Research Center of Oncology
I. A Pokataev
N.N. Blokhin National Medical Research Center of Oncology
O. V Sekhina
N.N. Blokhin National Medical Research Center of Oncology
D. A Chekini
N.N. Blokhin National Medical Research Center of Oncology
A. A Bulanov
N.N. Blokhin National Medical Research Center of Oncology
A. A Tryakin
N.N. Blokhin National Medical Research Center of Oncology
S. A Tyulyandin
N.N. Blokhin National Medical Research Center of Oncology
References
- Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl J. Med. 2004;350(23):2335-42.
- Jang H.J., Kim B.J., Kim J.H., Kim H. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated metaanalysis of randomized trials. Oncotarget. 2017;8(42):73 009-16. Doi: 10.18632/ oncotarget.20314.
- Орлов С.В., Фогт С.Н., Шустовр М.С. Успешная регистрация отечественного биоаналога бевацизумаба - новые возможности эффективной терапии больных неплоскоклеточным немелкоклеточным раком легкого. Исследования и практика в медицине. 2015;2(4):132-36.
- Reinacher-Schick A.C., Arnold D., Dietrich G., et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol. 2008;26:A4030.
- Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-44
- Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005;307:58-62
- Aparicio T., Ghiringhelli F., Boige V., et al. Bevacizumab maintenance Versus No Maintenance During Chemotherapy-Free Intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018 Mar 1,36(7): 674-81. doi: 10.1200/JCO.2017.75.2931.
- Hurwitz H.I., Tebbutt N.C., Kabbinavar F., et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18(9):1004-12. Doi: 10.1634/ theoncologist.2013-0107.
- Venook A.P., Niedzwiecki D., Innocents F., et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:3504.
- Hiret S., Christophe B., Bertaut A, et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 - UNICANCER GI). J Clin Oncol. 2016,34:3514.
Supplementary files
![](/img/style/loading.gif)